


### CLAIMS

- 5           1.     A pharmaceutical composition comprising a therapeutically effective amount of an Active Pharmaceutical Ingredient, a  $\beta$ -cyclodextrin, a pharmaceutically acceptable preservative, a pharmaceutically acceptable vehicle, and an optional pharmaceutically acceptable excipient, wherein the preservative demonstrates pharmaceutically acceptable antimicrobial preservative effectiveness.
- 10           2.     A pharmaceutical composition according to claim 1 wherein the Active Pharmaceutical Ingredient is a compound of Formula I,



I

- or its pharmaceutically acceptable salts, wherein R<sup>2</sup> is selected from the group consisting of methyl, ethyl, isopropyl, *sec*-butyl and *tert*-butyl.
- 15           3.     The pharmaceutical composition according to Claims 1 or 2 wherein the  $\beta$ -cyclodextrin is 2-hydroxypropyl-  $\beta$ -cyclodextrin or sulfobutyl ether- $\beta$ -cyclodextrin.
4.     The pharmaceutical composition according to any preceding claim wherein the preservative is selected from thimerosal, propylene glycol, phenol, or meta-cresol or a combination thereof.

5. The pharmaceutical composition according to any preceding claim wherein the preservative has a binding value to the cyclodextrin that is less than a binding value of the Active Pharmaceutical Ingredient to cyclodextrin.
6. The pharmaceutical composition according to any preceding claim wherein about 1 mg/mL to about 5 mg/mL of the preservative is unsequestered in the cyclodextrin.
7. The pharmaceutical composition according to any preceding claim wherein the binding value of the Active Pharmaceutical Ingredient to cyclodextrin is between  $500 \text{ M}^{-1}$  and  $10,000 \text{ M}^{-1}$ .
8. The pharmaceutical composition according to any preceding claim for use as a medicament.
9. The use of a composition according to any of Claims 2 to 7 in the manufacture of a medicament for the treatment of a disease for which a neurokinin receptor antagonist is indicated.
10. A method for the treatment of a disease for which a neurokinin receptor antagonist is indicated in mammals comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition of any of Claims 2 to 7.